Login to Your Account

Phase III Starts This Year

AtheroGenics To Try Heart Drug With Diabetes Subset

By Randall Osborne

Friday, June 1, 2007
About a week after AtheroGenics Inc. disclosed in SEC paperwork that the firm is saying goodbye to about half its work force, and slightly more than a month after partner AstraZeneca plc bailed out of a major deal for AGI-1067, the Phase III focus for that compound is shifting from atherosclerosis to diabetes. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription